Trials / Unknown
UnknownNCT05304637
Usability, Immediate, and 30 Day Effect of External Neuromodulation With iTEAR100 Generation 2 in Dry Eye Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Olympic Ophthalmics, Inc. · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
iTEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed.
Detailed description
TEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed. At both exam days, a Schirmer test before and after will be performed as well as parameters which indicate immediate effect of treatment and treatment over the 30 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | iTEAR100 treatment | Vibratory energy to the external nasal nerve |
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2022-06-01
- Completion
- 2022-07-01
- First posted
- 2022-03-31
- Last updated
- 2022-03-31
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05304637. Inclusion in this directory is not an endorsement.